16 October 2018

Highlights in Medicinal Chemistry III

Organised by:

SCI's Fine Chemicals Group

London, UK

This meeting aims to showcase vignettes of modern medicinal chemistry to bring new thinking to the subject, challenge perceptions and encourage scientific interaction between researchers. The short presentation format of the meeting also aims to provide a focussed forum to promote examples of medicinal chemistry excellence.
This meeting is targeted at academic and industrial scientists engaged in all aspects of the drug discovery process and those interested in broadening their knowledge at the forefront of medicinal chemistry.
09.20 Registration and refreshments
09.50 Opening remarks
09.55 Drug discovery beyond the rule of 5 - outer limits of oral absorption and insight into design at the extremes
Prof Jan Kihlberg, University of Uppsala, Sweden
10.35 Discovery of potent cyclophilin inhibitors based on structural simplification of Sanglifehrin A
Dr Vicky Steadman, Eurofins - Selcia, UK
11.00 The development of an intracellular degradation probe for pirin protein
Dr Nicola Chessum, Institute of Cancer Research, UK
11.25 Refreshment break
11.45 Potency and patents, new arenas for matched molecular pair analysis
Dr Edward Griffen, MedChemica Ltd, UK
12.10 Predictive computational approaches to guide the covalent targeting of cysteine residues in drug discovery
Dr Richard Ward, AstraZeneca, UK
12.35 Strategies for the design of brain penetrant kinase inhibitors
Dr Sarah Skerratt, Vertex Pharmaceuticals, UK
13.00 Lunch and exhibition
14.00 Structural insights into modulation of the orexin receptors
Dr John Christopher, Heptares, UK
14.25 From fragment to candidate for a protein-protein interaction target
Dr Rhian Holvey, Astex Pharmaceuticals, UK
14.50 Chemical strategies to achieve broad-spectrum antibacterial activity
Dr Alastair Parkes, Evotec Ltd, UK
15.30 Refreshment break
15.50 Discovery of a clinical candidate for the inhibition of DGAT2
Dr Rosario Gonzalez, Eli Lilly, Spain
16.15 Discovery and application of 3-oxabicyclo[4.1.0]heptane, a non-nitrogen containing morpholine isostere, through predictive Quantum Mechanical modelling
Dr Heather Hobbs, GlaxoSmithKline, UK
16.40 Synthesis-driven chemical biology and medicinal chemistry
Prof Matthew Gaunt, University of Cambridge, UK
17.20 Closing remarks
17.25 Networking and refreshments

Venue and Contact


14/15 Belgrave Square

Conference Team

Tel: +44 (0)20 7598 1561

Email: conferences@soci.org


Early bird fees before Monday 3 September 2018

One-Day Fee Two-Day Fee*
SCI Member £100 SCI Member £175
SCI Student Member £35 SCI Student Member £60
Non-Member £130 Non-Member £235

*The Two-Day Fee includes attendance at 'Designing Safer Medicines III' on Monday 15 October and 'Highlights in Medicinal Chemistry III' on Tuesday 16 October

Standard fees after Monday 3 September 2018

One-Day Fee Two-Day Fee*
SCI Member £115 SCI Member £205
SCI Student Member £40 SCI Student Member £70
Non-Member £150 Non-Member £270

Become an SCI Member and save on this and future events

See Membership Options

Sign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations

Booking Process
For bookings terms and conditions click here.
CPD Info
sci cpd


Organising Committee
  • Sarah Major, SCI / Evotec
  • Nigel Swain, SCI / Heptares
  • Al Dossetter, SCI / Mechemica Ltd
  • Joanne Pinder SCI / Vertex Pharmaceuticals
  • Iain Simpson SCI / AstraZeneca

Become an SCI Member to receive benefits and discounts

Join SCI